首页> 外文期刊>BMC Infectious Diseases >Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis
【24h】

Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis

机译:社区获得性肺炎的微生物病因,结局和住院费用;观察分析

获取原文
           

摘要

Background The aim of this study was to investigate the clinical outcome and especially costs of hospitalisation for community-acquired pneumonia (CAP) in relation to microbial aetiology. This knowledge is indispensable to estimate cost-effectiveness of new strategies aiming to prevent and/or improve clinical outcome of CAP. Methods We performed our observational analysis in a cohort of 505 patients hospitalised with confirmed CAP between 2004 and 2010. Hospital administrative databases were extracted for all resource utilisation on a patient level. Resource items were grouped in seven categories: general ward nursing, nursing on ICU, clinical chemistry laboratory tests, microbiology exams, radiology exams, medication drugs, and other.linear regression analyses were conducted to identify variables predicting costs of hospitalisation for CAP. Results Streptococcus pneumoniae was the most identified causative pathogen (25%), followed by Coxiella burnetii (6%) and Haemophilus influenzae (5%). Overall median length of hospital stay was 8.5?days, in-hospital mortality rate was 4.8%. Total median hospital costs per patient were €3,899 (IQR 2,911-5,684). General ward nursing costs represented the largest share (57%), followed by nursing on the intensive care unit (16%) and diagnostic microbiological tests (9%). In multivariate regression analysis, class IV-V Pneumonia Severity Index (indicative for severe disease), Staphylococcus aureus, or Streptococcus pneumonia as causative pathogen, were independent cost driving factors. Coxiella burnetii was a cost-limiting factor. Conclusions Median costs of hospitalisation for CAP are almost €4,000 per patient. Nursing costs are the main cause of these costs.. Apart from prevention, low-cost interventions aimed at reducing length of hospital stay therefore will most likely be cost-effective.
机译:背景技术这项研究的目的是调查与微生物病因相关的社区获得性肺炎(CAP)的临床结局,尤其是住院费用。该知识对于评估旨在预防和/或改善CAP临床结果的新策略的成本效益必不可少。方法我们对2004年至2010年间经确诊CAP住院的505例患者进行了观察性分析。提取了医院管理数据库以获取患者水平的所有资源。资源项目分为七个类别:普通病房护理,ICU护理,临床化学实验室检查,微生物学检查,放射学检查,药物治疗和其他。进行线性回归分析以识别预测CAP住院费用的变量。结果肺炎链球菌是最易确定的病原体(25%),其次是伯氏柯氏杆菌(6%)和流感嗜血杆菌(5%)。总体住院时间中位数为8.5天,住院死亡率为4.8%。每位患者的总住院费用中位数为3,899欧元(IQR 2,911-5,684)。普通病房护理费用所占比例最大(57%),其次是重症监护病房的护理(16%)和诊断性微生物学检查(9%)。在多元回归分析中,IV-V级肺炎严重程度指数(指示严重疾病),金黄色葡萄球菌或肺炎链球菌是致病菌,是独立的成本驱动因素。伯氏柯氏杆菌是限制成本的因素。结论CAP的住院费用中位数约为每名患者4,000欧元。护理费用是造成这些费用的主要原因。.除了预防以外,旨在减少住院时间的低成本干预措施很可能会具有成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号